INTERVENTION 1:	Intervention	0
Arm A: FAC	Intervention	1
FAC X 6 The standard arm consisted of six cycles of FAC (fluorouracil 500 mg/m2, doxorubicin 50mg/m2, and cyclophosphamide 500mg/m2) administered once every 3 weeks.	Intervention	2
x	LABO:0000148	4-5
x	LABO:0000148	40-41
x	LABO:0000148	83-84
doxorubicin	CHEBI:28748,BAO:0000639	81-92
cyclophosphamide	CHEBI:4026	106-122
INTERVENTION 2:	Intervention	3
Arm B: FAC-wP	Intervention	4
FAC X 4 + 8 weekly Paclitaxel (wP) Patients in the experimental arm received four cycles of the FAC regimen followed by eight weekly administrations of paclitaxel (100mg/m2 per dose)	Intervention	5
x	LABO:0000148	4-5
x	LABO:0000148	26-27
x	LABO:0000148	52-53
x	LABO:0000148	159-160
paclitaxel	CHEBI:45863	19-29
paclitaxel	CHEBI:45863	152-162
Inclusion Criteria:	Eligibility	0
Written informed consent.	Eligibility	1
Histological diagnoses of operable invasive adenocarcinoma of the breast (T1-T3). Tumors must be Human Epidermal Growth Factor Receptor 2 (HER2) negative. Patients must be free of disease in the axilla (node negative). If lymphadenectomy is done, at least 10 nodes must be examined. If sentinel node technique is used, sentinel node must be free of disease. Patients must present at least one high risk criterion (St. Gallen, 1998) as follows:	Eligibility	2
adenocarcinoma	DOID:299	44-58
breast	UBERON:0000310	66-72
growth factor	BAO:0002024	113-126
receptor	BAO:0000281	127-135
disease	DOID:4,OGMS:0000031	180-187
disease	DOID:4,OGMS:0000031	349-356
present	PATO:0000467	372-379
Tumor size > 2 cm; and/or	Eligibility	3
size	PATO:0000117	6-10
ER and Progesterone Receptor (PgR) negative; and/or	Eligibility	4
progesterone	CHEBI:17026	7-19
receptor	BAO:0000281	20-28
Histological grade 2-3; and/or	Eligibility	5
Age < 35 years old.	Eligibility	6
age	PATO:0000011	0-3
Time window between surgery and study randomization must be less than 60 days.	Eligibility	7
time	PATO:0000165	0-4
surgery	OAE:0000067	20-27
Surgery must consist of mastectomy or conservative surgery. Margins free of disease and ductal carcinoma in situ (DCIS) are required. Lobular carcinoma is not considered a positive margin.	Eligibility	8
surgery	OAE:0000067	0-7
surgery	OAE:0000067	51-58
disease	DOID:4,OGMS:0000031	76-83
ductal carcinoma in situ	HP:0030075,DOID:0060074	88-112
carcinoma	HP:0030731,DOID:305	95-104
carcinoma	HP:0030731,DOID:305	142-151
Patients must not present evidence of metastatic disease.	Eligibility	9
present	PATO:0000467	18-25
disease	DOID:4,OGMS:0000031	49-56
Status of hormone receptors in primary tumor. Results must be available before the end of adjuvant chemotherapy.	Eligibility	10
hormone	CHEBI:24621	10-17
adjuvant	CHEBI:60809	90-98
Status of HER2 in primary tumor, known before randomization. Patients with Immunohistochemistry (IHC) 0 or +1 are eligible. For patients with IHC 2+, fluorescent in situ hybridization (FISH) is mandatory and result must be negative.	Eligibility	11
immunohistochemistry	BAO:0000415	75-95
result	BAO:0000179	208-214
Age >= 18 and <= 70 years old.	Eligibility	12
age	PATO:0000011	0-3
Performance status (Karnofsky index) >= 80.	Eligibility	13
Normal electrocardiogram (EKG) in the 12 weeks prior to randomization. If needed, normal cardiac function must be confirmed by left ventricular ejection fraction (LVEF).	Eligibility	14
function	BAO:0003117,BFO:0000034	97-105
left	HP:0012835	127-131
ejection fraction	CMO:0000180	144-161
Laboratory results (within 14 days prior to randomization):	Eligibility	15
Hematology: neutrophils >= 1.5 x 10^9/l; platelets >= 100x 10^9/l; hemoglobin >= 10 mg/dl;	Eligibility	16
x	LABO:0000148	31-32
x	LABO:0000148	57-58
hemoglobin	CHEBI:35143	67-77
Hepatic function: total bilirubin <= 1 upper normal limit (UNL); Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) <= 2.5 UNL; alkaline phosphatase <= 2.5 UNL. If values of AST and ALT > 1.5 UNL are associated with alkaline phosphatase > 2.5 UNL, patient is not eligible.	Eligibility	17
function	BAO:0003117,BFO:0000034	8-16
aspartate	CHEBI:29995	65-74
alanine	CHEBI:16449	102-109
phosphatase	GO:0016791,BAO:0000295	154-165
phosphatase	GO:0016791,BAO:0000295	242-253
patient	HADO:0000008,OAE:0001817	265-272
Renal function: creatinine <= 175 mmol/l (2 mg/dl); creatinine clearance >= 60 ml/min.	Eligibility	18
function	BAO:0003117,BFO:0000034	6-14
creatinine	CHEBI:16737	16-26
creatinine	CHEBI:16737	52-62
creatinine clearance	CMO:0000765	52-72
Complete stage workup during the 12 weeks prior to randomization (mammograms are allowed within a 20 week time window). All patients must have a bilateral mammogram, thorax x-ray, abdominal echography and/or computed tomography (CT)-scan. If bone pain, and/or alkaline phosphatase elevation, a bone scintigraphy is mandatory. This test is recommended for all patients. Other tests, as clinically indicated.	Eligibility	19
week	UO:0000034	36-40
week	UO:0000034	101-105
time	PATO:0000165	106-110
bilateral	HP:0012832	145-154
tomography	BAO:0002525	217-227
ct	BAO:0002125	229-231
bone pain	HP:0002653	242-251
phosphatase	GO:0016791,BAO:0000295	269-280
Patients able to comply with treatment and study follow-up.	Eligibility	20
Negative pregnancy test done in the 14 previous days to randomization.	Eligibility	21
Exclusion Criteria:	Eligibility	22
Prior systemic therapy for breast cancer.	Eligibility	23
breast cancer	DOID:1612	27-40
Prior therapy with anthracyclines or taxanes (paclitaxel or docetaxel) for any malignancy.	Eligibility	24
paclitaxel	CHEBI:45863	46-56
Prior radiotherapy for breast cancer.	Eligibility	25
radiotherapy	OAE:0000235	6-18
breast cancer	DOID:1612	23-36
Bilateral invasive breast cancer.	Eligibility	26
bilateral	HP:0012832	0-9
breast cancer	DOID:1612	19-32
Pregnant or lactating women. Adequate contraceptive methods must be used during chemotherapy and hormone therapy treatments. Negative pregnancy test in the 14 previous days to randomization.	Eligibility	27
hormone	CHEBI:24621	97-104
Any T4 or N1-3 or M1 tumor.	Eligibility	28
m1	CHEBI:34826	18-20
HER2 positive breast cancer (IHC 3+ or positive FISH result).	Eligibility	29
breast cancer	DOID:1612	14-27
result	BAO:0000179	53-59
Pre-existing grade >=2 motor or sensorial neurotoxicity by the National Cancer Institute Common Toxicity Criteria (NCICTC) v-2.0.	Eligibility	30
cancer	DOID:162	72-78
Any other serious medical pathology, such as congestive heart failure, unstable angina, history of myocardial infarction during the previous year, uncontrolled hypertension or high risk arrhythmias.	Eligibility	31
congestive heart failure	HP:0001635,DOID:6000	45-69
history	BFO:0000182	88-95
myocardial infarction	HP:0001658,DOID:5844	99-120
year	UO:0000036	141-145
hypertension	HP:0000822,DOID:10763	160-172
History of neurological or psychiatric disorders, which could preclude the patients to free informed consent.	Eligibility	32
history	BFO:0000182	0-7
Active uncontrolled infection.	Eligibility	33
active	PATO:0002354	0-6
Active peptic ulcer; unstable diabetes mellitus.	Eligibility	34
active	PATO:0002354	0-6
peptic ulcer	HP:0004398	7-19
diabetes mellitus	HP:0000819,DOID:9351	30-47
Previous or current history of neoplasms different from breast cancer, except for skin carcinoma, cervical in situ carcinoma, or any other tumor curatively treated and without recurrence in the last 10 years; ductal in situ carcinoma in the same breast; lobular in situ carcinoma.	Eligibility	35
history	BFO:0000182	20-27
breast cancer	DOID:1612	56-69
skin carcinoma	DOID:3451	82-96
in situ carcinoma	DOID:8719	107-124
in situ carcinoma	DOID:8719	216-233
in situ carcinoma	DOID:8719	262-279
breast	UBERON:0000310	56-62
breast	UBERON:0000310	246-252
Concomitant treatment with other investigational products. Participation in other clinical trials with a non-marketed drug in the 20 previous days before randomization.	Eligibility	36
drug	CHEBI:23888	118-122
Concomitant treatment with other therapy for cancer.	Eligibility	37
cancer	DOID:162	45-51
Males.	Eligibility	38
Outcome Measurement:	Results	0
Disease-free Survival (DFS) Event	Results	1
DFS is defined as the evidence of local, regional or metastatic recurrence, second primary cancer (with the exception of carcinoma of squamous cells or basal cells of the skin, cervical carcinoma in situ or lobular or ductal carcinoma in situ of the breast) or death for any reason.	Results	2
second	UO:0000010	76-82
cancer	DOID:162	91-97
carcinoma	HP:0030731,DOID:305	121-130
carcinoma	HP:0030731,DOID:305	186-195
carcinoma	HP:0030731,DOID:305	225-234
ductal carcinoma in situ	HP:0030075,DOID:0060074	218-242
breast	UBERON:0000310	250-256
death	OAE:0000632	261-266
Time frame: Up to 5 years	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Arm A: FAC	Results	5
Arm/Group Description: FAC X 6 The standard arm consisted of six cycles of FAC (fluorouracil 500 mg/m2, doxorubicin 50mg/m2, and cyclophosphamide 500mg/m2) administered once every 3 weeks.	Results	6
x	LABO:0000148	27-28
x	LABO:0000148	63-64
x	LABO:0000148	106-107
doxorubicin	CHEBI:28748,BAO:0000639	104-115
cyclophosphamide	CHEBI:4026	129-145
Overall Number of Participants Analyzed: 974	Results	7
Measure Type: Count of Participants	Results	8
Unit of Measure: Participants  98  10.1%	Results	9
Results 2:	Results	10
Arm/Group Title: Arm B: FAC-wP	Results	11
Arm/Group Description: FAC X 4 + 8 weekly Paclitaxel (wP) Patients in the experimental arm received four cycles of the FAC regimen followed by eight weekly administrations of paclitaxel (100mg/m2 per dose)	Results	12
x	LABO:0000148	27-28
x	LABO:0000148	49-50
x	LABO:0000148	75-76
x	LABO:0000148	182-183
paclitaxel	CHEBI:45863	42-52
paclitaxel	CHEBI:45863	175-185
Overall Number of Participants Analyzed: 951	Results	13
Measure Type: Count of Participants	Results	14
Unit of Measure: Participants  71   7.5%	Results	15
Adverse Events 1:	Adverse Events	0
Total: 60/974 (6.16%)	Adverse Events	1
Febrile neutropenia *  [1]31/974 (3.18%)	Adverse Events	2
neutropenia	HP:0001875,DOID:1227	8-19
Neutropenia *  [2]6/974 (0.62%)	Adverse Events	3
neutropenia	HP:0001875,DOID:1227	0-11
Neutropenia *  [1]3/974 (0.31%)	Adverse Events	4
neutropenia	HP:0001875,DOID:1227	0-11
Neutropenia *  [3]2/974 (0.21%)	Adverse Events	5
neutropenia	HP:0001875,DOID:1227	0-11
Leukocytes *  [4]1/974 (0.10%)	Adverse Events	6
Hemoglobin *  [1]0/974 (0.00%)	Adverse Events	7
hemoglobin	CHEBI:35143	0-10
Thrombosis/embolism *  [1]1/974 (0.10%)	Adverse Events	8
Thrombosis/embolism *  [2]0/974 (0.00%)	Adverse Events	9
Cardiac-ischemia/infarction *  [2]0/974 (0.00%)	Adverse Events	10
Adverse Events 2:	Adverse Events	11
Total: 61/951 (6.41%)	Adverse Events	12
Febrile neutropenia *  [1]18/951 (1.89%)	Adverse Events	13
neutropenia	HP:0001875,DOID:1227	8-19
Neutropenia *  [2]1/951 (0.11%)	Adverse Events	14
neutropenia	HP:0001875,DOID:1227	0-11
Neutropenia *  [1]1/951 (0.11%)	Adverse Events	15
neutropenia	HP:0001875,DOID:1227	0-11
Neutropenia *  [3]1/951 (0.11%)	Adverse Events	16
neutropenia	HP:0001875,DOID:1227	0-11
Leukocytes *  [4]0/951 (0.00%)	Adverse Events	17
Hemoglobin *  [1]1/951 (0.11%)	Adverse Events	18
hemoglobin	CHEBI:35143	0-10
Thrombosis/embolism *  [1]3/951 (0.32%)	Adverse Events	19
Thrombosis/embolism *  [2]3/951 (0.32%)	Adverse Events	20
Cardiac-ischemia/infarction *  [2]1/951 (0.11%)	Adverse Events	21
